Peptipedia
HormonalFDA ApprovedFDA Approved

Pasireotide

Also known as Signifor, Signifor LAR

A somatostatin analog with broader receptor binding than octreotide, particularly effective for Cushing's disease due to SST5 receptor activity.

FDA Approved - Cushing's disease and acromegaly
CompareFind Vendors

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

300-900 mcg twice daily (SC) or 40-60 mg monthly (LAR)

Frequency

Twice daily (SC) or monthly (LAR)

Duration

Long-term / chronic use

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 300-900 mcg twice daily (SC) or 40-60 mg monthly (LAR) via Subcutaneous or intramuscular, Twice daily (SC) or monthly (LAR). Dose range: 600-900 mcg SC twice daily; 40-60 mg IM monthly. Duration: Long-term / chronic use.

Timing & Administration

Administer via Subcutaneous or intramuscular. Frequency: Twice daily (SC) or monthly (LAR).

Mechanism of Action

Binds to somatostatin receptors 1, 2, 3, and 5 with high affinity. SST5 binding is particularly important for suppressing ACTH secretion from corticotroph adenomas.

Research Summary

Evidence level: fda approved. Clinical status: FDA Approved - Cushing's disease and acromegaly.

Side Effects & Safety

Important Warnings

  • QT prolongation risk
  • High incidence of hyperglycemia.
Hyperglycemia and diabetes (very common)
diarrhea
nausea
gallstones
QT prolongation (serious)
liver enzyme elevations
adrenal insufficiency

References

No references available.

Related Peptides

Browse all →
OxytocinHormonal

A naturally occurring peptide hormone essential for social bonding, childbirth, and lactation. Under investigation for autism, anxiety, and social disorders.

View profile
GonadorelinHormonal

A synthetic version of gonadotropin-releasing hormone used diagnostically and therapeutically for reproductive conditions.

View profile
LeuprolideHormonal

A GnRH agonist suppressing testosterone and estrogen production, approved for prostate cancer, endometriosis, uterine fibroids, and precocious puberty.

View profile